瑞舒伐他汀辅助治疗阵发性房颤对患者血浆超敏-C反应蛋白和肿瘤坏死因子-α水平影响

Influence and Curative Effect Observation of Rosuvastatin adjunctive therapy on Plasma High Sensitivity-C Reactive Protein and Tumor Necrosis Factor-α Levels of Patients with Paroxysmal Atrial Fibrillation

目的:观察瑞舒伐他汀辅助治疗阵发性房颤的疗效及对患者血浆超敏-C反应蛋白(hs-CRP)和肿瘤坏死因子-α(TNF-α)水平的影响。方法:90例阵发性心房颤动患者随机分为观察组及对照组。两组均予口服胺碘酮片治疗,第1周200 mg,tid,第2周200 mg,bid,此后改为200 mg,qd。观察组在此基础上加服瑞舒伐他汀片10 mg,po,qd。两组疗程均为12个月。观察两组患者治疗前后血脂、血浆hs-CRP和TNF-α水平变化,并比较两组临床疗效及安全性评价。结果:治疗12个月后,观察组患者TC、TG和LDL-C水平均较治疗前明显下降,HDL-C则明显上升(P<0.05),而对照组治疗前后无明显变化(P>0.05);两组患者hs-CRP和TNF-α水平较前明显下降(P<0.01或0.05),观察组比对照组降低更明显(P<0.05)。观察组临床总有效率为77.78%,明显高于对照组的57.78%(P<0.05);两组药品不良反应发生率比较,差异无统计学意义(P>0.05)。结论:瑞舒伐他汀辅助治疗阵发性房颤的疗效确切,安全性好,具有良好的调脂作用,可降低患者血浆hs-CRP和TNF-α水平,具有抑制炎症反应作用。

Objective：To observe the influence and curative effect observation of rosuvastatin adjunctive therapy on plasma high sensitivity -C reactive protein （hs-CRP） and tumor necrosis factor-ct （TNF-ct） levels of patients with paroxysmal atrial fibrillation. Methods ：90 cases of patients with paroxysmal atrial fibrillation were divided randomly into obser- vation group and control group . The patients in two groups were given amiodarone through the mouth with load capacity of 200mg per time, three times a day for the first week, 200mg per time twice a day for the second week, and aequum capacity of 200mg per time once a day for the following weeks until the end of the test. The patients in observation group were additionally given 10mg rosuvastatin once a day. The courses of medical treatment of patients in two groups were both 12 months. The changes of plasma hs-CRP and TNF- a levels of patients in two groups before and after medical treatment were observed, and curative effect and security evaluation was carried on as well. Results：After 12 months＇ medical treatment, the TC, TG and LDL-C levels of patients in observation group were declined obviously than before, while HDL-C were rose obviously than before （P 〈 0.05 ）, and the TC, TG , HDL-C and LDL-C levels had no obviously changes in control group. And hs-CRP and TNF- ct levels of patients in two groups obviously declined than before（ P 〈 0.01 or P 〈 0.05 ）, and the declining rate of patients in observation group was much higher than that in control group （ P 〈 0.05 ）. The total clinical efficiency of patients in observation group was 77.78%, which was much higher than that in control group （57.78%） （P 〈 0.05 ）. The occurrence rates of adverse drug reactions of patients in observation group and control group were both low, and without statistical difference after comparison （ P 〉 0.05 ）. Conclusion ： Rosuvastatin adjunctive therapy has reliable curative effect and good lipid regulating effects on paroxysmal atrial fibrillation, with high security, which can reduce the plasma hs-CRP and TNF- a levels of patients with the anti-inflammation reaction effect.